Abstract
In glioma, kinesin family member 23 (KIF23) is up-regulated and plays a vital role in oncogenesis. However, the mechanism underlying KIF23 overexpression in malignant glioma remains to be elucidated. This study aims to find potential causes of KIF23 high expression at genome level. To clarify this issue, we obtained point mutation and copy number alterations (CNAs) of KIF23 in 319 gliomas using whole-exome sequencing. Only two glioma samples with missense mutations in KIF23 coding region were identified, while 7 patients were detected with amplification of KIF23. Additional analysis showed that KIF23 amplification was significantly associated with higher expression of KIF23. Gene ontology analysis indicated that higher copy number of KIF23 was associated TNF-α signaling pathway and mitotic cell circle checkpoint, which probably caused by subsequent upregulated expression of KIF23. Moreover, pan-cancer analysis showed that gaining of copy number was significantly associated with higher expression of KIF23, consolidating our findings in glioma. Thus, it was deduced that elevated KIF23 expression in glioma tended to be caused by DNA copy number amplification, instead of mutation.
Introduction
Kinesin family member 23 (KIF23) is a nuclear protein and plays a key role in regulating cytokinesis (; ; ). It has been found to be dysregulated and act as an oncogene with prognostic value in various tumors (; ; ). Our previous study showed that KIF23 mRNA expression was positively correlated with glioma grade, and high KIF23 expression conferred poor survival in glioma, which was further validated by the TCGA, REMBRANDT, and GSE16011 database (). These results indicated that dysregulated KIF23 may play an essential role in tumorigenesis and progression, but how KIF23 expression is upregulated in cancers remains unelucidated.
Previous study showed that in the tumors with up-regulated KIF23 expression, DNA mutation of KIF23 was detected in nearly half of tested human cancer types, and CNAs of KIF23 showed gain in 30% of tested tumors (). Besides, p.P916R mutation of KIF23 causes a rare hereditary form of dyserythropoietic anemia (CDA III) with predisposition to blood cancer (), and they further demonstrated that overexpression of KIF23 in non-small-cell lung cancer might be caused by CNAs (). The above studies indicated that KIF23 gene expression can be modulated either by DNA mutation or by CNAs. However, KIF23 mutation and CNAs status in glioma is unclear. Given the idea that KIF23 is a novel prognostic biomarker with potential therapeutic implications in glioma, it is valuable to investigate the mutation and CNAs status of KIF23 in glioma.
In this study, we screened for KIF23 DNA mutation and CNAs in 319 gliomas with DNA and RNA sequencing data, and demonstrated that elevated KIF23 expression in glioma was probably caused by DNA copy number amplification. In terms of the important role of KIF23 in tumorigenesis and malignant aggressive progression of glioma, further understanding of its functional mechanism and pathway should be investigated.
Materials and Methods
RNA-Sequencing Data
Two independent RNA-seq datasets (mRNAseq_325 and mRNAseq_693) and paired clinical information were obtained from Chinese Glioma Genome Atlas (CGGA) database1 (). In the two datasets, only samples with definite WHO classification were included for survival and grade expression pattern analysis. Thus, 321 glioma samples (103 WHO grade II, 79 WHO grade III and 139 WHO grade IV) of CGGA mRNAseq_325 dataset, 692 glioma samples (188 WHO grade II, 255 WHO grade III, and 249 WHO grade IV) of CGGA mRNAseq_693 dataset were enrolled for subsequent analysis.
Whole-Exome Sequencing (WES) Data
Genomic DNA from tumor and matched blood sample was extracted and confirmed for high integrity by 1% agarose gel electrophoresis. The DNA was subsequently fragmented, quality-controlled, and then pair-end libraries were prepared. For whole exome sequencing, Agilent SureSelect kit v6 was used for target capture. Sequencing was done on Illumina Hiseq platform using 150 bp pair-end sequencing strategy. In total, 319 whole-exome sequencing data of glioma samples were obtained, which were also available at CGGA Network.
DNA sequencing data were then mapped to the reference human genome (UCSC hg19) using Burrows-Wheeler Aligner (version 0.7.12-r1039, bwa mem) () with default parameters. Then, SAMtools (version 1.2) () and Picard (version 2.0.1, Broad Institute)2 were used to sort the reads by coordinates and mark duplicates. Statistics such as sequencing depth and coverage were calculated based on the resultant BAM files. SAVI2 was used to identify somatic mutations (including single nucleotide variations and short insertion/deletions) as previously described (; ). In this pipeline, SAMtools mpileup and bcftools were used to perform variant calling, then the preliminary variant list was filtered to remove positions with no sufficient sequencing depth, positions with only low-quality reads, and positions that are biased toward either strand. Somatic mutations were identified and evaluated by an Empirical Bayesian method. In particular, mutations with significantly higher allele frequency in tumors than that in normal control were selected. Additionally, CNVkit (version 0.9.4.dev0)() was used to detect copy number changes from WES data.
Gene Set Enrichment Analysis
Firstly, we obtain the KIF23 CNV status WES data from CGGA database3 and Cancer Hallmarks associated geneset from GSEA website4 version 7.2. By integrating the WES data and matched RNA-seq data, we calculated the fold change of gene expression for each gene between KIF23 with or without CNV. Next, we use R package GSVA (version 1.36.3) to do enrichment analysis in cancer hallmarks.
Statistical Analysis
Statistical analysis was performed using SPSS Graduate Pack (version 16.0) and GraphPad Prism (version 5.0) statistical software. Descriptive statistics were shown as mean ± standard deviation. Student’s t test, one-way ANOVA test were used to test the significance of differences. Overall survival time (OS) was calculated from the date of histological diagnosis until death or the last follow-up. Kaplan-Meier survival analysis was used to estimate the survival distributions, and log-rank test was used to assess the statistical significance between stratified survivals groups. Patients with KIF23 expression lower than median level of KIF23 was defined as low expression, while patients with higher than the median value or equal to the median one was defined as high expression. A two-sided p value < 0.05 was considered statistically significant.
Results
KIF23 Expression Is Positively Correlated With Tumor Grade and Confers Poor Survival in Glioma
To validate the results of our previous study (), we analyzed KIF23 expression pattern using CGGA mRNAseq_325 and mRNAseq_693 datasets. We got the similar results that KIF23 expression was the highest in grade IV glioma group, while had the lowest expression in grade II glioma group (p < 0.001) (Figures 1A,B). Besides, we also found that patients with high KIF23 expression (median survival in CGGA_mRNAseq_325 dataset is 386 days, and CGGA mRNAseq_693 dataset is 530 days) had a significantly worse overall survival compared to those with low KIF23 expression (median survival in CGGA mRNAseq_693 dataset is 3174 days, and CGGA mRNAseq_693 dataset is 2982 days) (p < 0.001) (Figures 1C,D).
FIGURE 1
Mutation Analysis of KIF23 in Glioma
Tumor DNA from 319 glioma patients were available for calling mutations, as shown in Figure 2. The mutation rate of IDH1 and TP53 was 53% and 48%, respectively. However, KIF23 mutation rate was less than 1% (Figure 2A). Only two case-specific missense mutations were detected, including non-synonymous change 69733357 G > A in Case104 and 69728081 C > T in Case241 (Table 1). Our results showed that patients with KIF23 mutation (median survival is 530 days) had a significantly worse overall survival compared to those without KIF23 mutation (median survival is 2982 days) (p = 0.025) (Figure 2B).
FIGURE 2
TABLE 1
| Sample ID | Cancer type | Chromosome | Mutation position | Reference allele | Variant allele | AA change |
| Case104 | Recurrent GBM | 15 | 69733357 | G | A | G773D |
| Case 241 | Recurrent GBM | 15 | 69728081 | C | T | P415S |
Case-specific non-synonymous mutation of KIF23 in 2 glioma samples.
CNAs Analysis of KIF23 in Glioma
CNAs were analyzed from the above WES data with 319 samples. We defined log ratio > 0.25 as Amplification group (n = 11), log ratio < -0.25 as Deletion group (n = 40), others as Wildtype group (n = 268). As shown in Figure 3A, KIF23 expression was the highest in Amplification group. Though there’s no significant difference between Deletion group and Wildtype group, KIF23 in Wildtype group still showed relatively higher expression than that in Deletion group. The expression pattern was also independently validated in TCGA dataset (Figure 3B). Furthermore, we explored other focal CNAs in both low- and high-expression of KIF23 groups. We identified several significantly well-characterized genetic alterations in the case with high KIF23 expression (Table 2), such as PTEN loss (p value = 7.37e-8), CDKN2A loss (p value = 4.04e-12), CDKN2B loss (p value = 9.44e-12), KIT gain (p value = 3.33e-7), PDGFRA gain (p value = 5.06e-7), MET gain (p value = 1.30-04) and CDK6 gain (p value = 3.06e-04). Furthermore, we explore the KIF23 CNVs in Pan-cancer levels from TCGA datasets. Our results showed that KIF23 CNVs occurred in various human cancers (Figure 3C), including endometrial carcinoma, melanoma and gliomas, suggesting KIF23 as a critical role in pan-cancer. Moreover, pan-cancer analysis showed that gaining of copy number was significantly associated with higher expression of KIF23, consolidating our findings in glioma (Figure 3D). Network analysis revealed that KIF23 was tightly involved in mitosis, by interacting actively with genes such as CDK1 and CDCA8 (Figure 3E).
FIGURE 3
TABLE 2
| Alteration | Alt in exphigh | Alt in explow | WT in exphigh | WT in explow | P value |
| PTEN_loss | 90 | 42 | 70 | 117 | 7.37e-08 |
| CDKN2A_loss | 104 | 42 | 56 | 117 | 4.04e-12 |
| CDKN2B_loss | 104 | 43 | 56 | 116 | 9.44e-12 |
| KIT_gain | 46 | 11 | 114 | 148 | 3.33e-07 |
| PDGFRA_gain | 47 | 12 | 113 | 147 | 5.06e-07 |
| MET_gain | 58 | 27 | 102 | 132 | 1.30e-04 |
| CDK6_gain | 51 | 23 | 109 | 136 | 3.06e-04 |
Significant CNA events between KIF67 high expression and low expression groups.
Amplification of KIF23 Is a Negative Prognosticator for Glioma Patients
Since higher expression of KIF23 was negatively associated with overall survival with patients, we further investigated the prognostic value of KIF23 amplification with 319 glioma samples. As what was expected (Figure 4), patient with copy number gaining of KIF23 showed significantly worse survival than those without KIF23 amplification (log-rank test, p value = 0.033). This result was in consistence with the prognostic value of KIF23 high expression, which consolidates the role of KIF23 in glioma pathophysiology processes.
FIGURE 4
Higher Copy Number of KIF23 Is Significantly Associated With TNF-α Signaling Pathway and Cellular Mitotic Activities
To explore the underlying mechanism of amplification of KIF23, we conducted gene ontology analysis for KIF23 copy number variation. Enrichment analysis revealed that KIF23 copy number positively associated genes tended to be associated with active cell biological process (Figure 5A), including TNF-α signaling pathway (Figure 5B), and G2M checkpoint (Figure 5C). These results indicated that higher copy number of KIF23 was involved with active immune activities and mitotic cellular activities, which further suggested more malignant biological processes. This is consistent with what we have found in the analysis of expression of KIF23, consolidating the malignant role of KIF23 in glioma.
FIGURE 5
Discussion
KIF23, also known as MKLP1 (mitotickinesin-like protein-1), is a member of kinesin-like motor protein superfamily. The protein encoded by KIF23 contains the kinesin superfamily motor domain at the N-terminal region. The domain mainly localizes in the interzone of mitotic spindles and acts as a plus-end-directed motor enzyme that moves along anti-parallel microtubules (). KIF23 has been identified as a key regulator of cytokinesis for its essential role in spindle midbody formation (; ). Antagonism of KIF23 expression causes cell growth inhibition, and the formation of enlarged cell bodies with binuclear/multinuclear in many tumor cells (; ; ), probably due to the cell cycle arrest which further caused mitosis failure.
It seems that elevated of KIF23 expression is a common event in various human cancers. KIF23 was reported to be overexpressed in pancreatic ductal adenocarcinoma (), malignant pleural mesothelioma (), lung cancer (; ), breast cancer (), hepatocellular carcinoma (HCC) (; ), gastric cancer (; ), and ovarian cancer (; ). Interestingly, most studies also showed that patients with higher KIF23 expression had worse prognosis survival compared to these with lower KIF23 expression (; ; ; ). All these studies indicated that KIF23 plays as an oncogene in cancers. In glioma, KIF23 was also showed to be up-regulated compared to normal brain samples, and inhibition of KIF23 suppressed the proliferation of glioma cells both in vivo and in vitro. Furthermore, high KIF23 expression also conferred poor survival in glioma patients (; ). However, these two studies only employed 11 and 54 glioma samples, respectively. To further validate the above results, we investigated KIF23 expression pattern and its relationship with clinical features in glioma based on 305 samples from CGGA whole genome mRNA expression microarray data in our previous study. The analysis showed that: (1) KIF23 expression was positively correlated with tumor malignancy (grade, wild-type IDH1, G3, and Mesenchymal subtype preference), (2) patients with higher expression of KIF23 had a shorter survival time than those with lower KIF23 expression, and (3) KIF23 was an independent prognostic biomarker for glioma patients. We also demonstrated that reduction of KIF23 expression significantly suppressed U87MG cells proliferation in vitro and intracranial tumor growth in vivo, as well as prolonged intracranial glioma mice’s overall survival days (). All these researches indicated the potential value of KIF23 as therapeutic target in tumors. Thus, it is urgent and valuable to clarify the signaling pathway of KIF23, as well as the reason which caused its abnormal expression.
One study assumed that mutation in the CHR of KIF23 promoter may cause increased KIF23 expression (). In another study, employed a mutation screening of the KIF23 in 15 non-small-cell lung cancer (NSCLC) cases with elevated expression level of KIF23, however, none of the examined samples had the mutation in the CHR of KIF23 by using sanger sequencing and single nucleotide polymorphism (SNP)-array. Interestingly, by assessment of CNAs in these samples, they concluded the elevated level of KIF23 might be due to additional copy of chromosome 15. In other researches, KIF23 p.R671W mutation was detected in one family with colorectal cancer (). Melanoma cells derived from metastatic lesions patients also found KIF23 mutation by whole-exome sequencing and SNP array profiling (). Furthermore, KIF23 mutation was detected in about half of 38 tested tumor types (20 out of 38 were confirmed with elevated KIF23 expression). Additionally, CNAs analysis showed that gain in three out of ten tumors, loss in two type of cancer and five tumors confirmed with both gain and loss (; ). Based on the hypothesis that the presence of activating somatic mutation or CNAs may cause KIF23 overexpression, we first evaluated the KIF23 expression pattern and prognosis value in CGGA 325 and 693 RNA sequencing database. The results showed that KIF23 expression was positively correlated with tumor grade. Moreover, higher KIF23 expression conferred poor survival, which was consistent with our previous study (). In order to investigate KIF23 somatic mutation and CNAs in glioma, we then screened the 319 glioma samples by using whole-exome sequencing analysis from CGGA database. However, only two case-specific non-synonymous mutations were detected. KIF23 mutation rate was less than 1% in our dataset. Next, we classified the 319 gliomas into CNAs Deletion group, Wildtype group, and Amplification group according to the log ratio. Then, the KIF23 gene expression was calculated, and a positive correlation was detected between KIF23 FPKM expression values and CNA. CNAs associated gene ontology revealed that KIF23 amplification was involved with active immune response and mitotic cell activities, which was consistent with the function of KIF23 expression in our previous paper. These results indicated that DNA copy number amplification may potentially contribute to elevated KIF23 expression in glioma while the biological effects of nucleotide mutation in KIF23 warrants additional investigation.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.
Author contributions
L-HS, ZZ, and ZW contributed to study concept and design. ZZ, ZW, Z-SB, W-ZG, and Y-DZ contributed to acquisition of data. C-JR, TL, and YW contributed to analysis and interpretation of data. L-HS, ZZ, and ZW contributed to draft of the manuscript. All authors contributed to the article and approved the submitted version.
Funding
The study was funded by National Natural Science Foundation of China (Nos. 81302183 and 81902528), National Natural Science Foundation of China (NSFC)/Research Grants Council (RGC) Joint Research Scheme (81761168038), and Beijing Municipal Administration of Hospitals’ Mission Plan (SML20180501, 2018.03-2022.02).
Acknowledgments
We would like to thank Hua Huang and Chengyin Liu from Beijing Neurosurgical Institute for collecting tumor samples and clinical follow-up. Furthermore, we appreciate the generosity of TCGA for sharing the huge amount of genetic sequencing data.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Footnotes
References
1
CeramiE.GaoJ.DogrusozU.GrossB. E.SumerS. O.AksoyB. A.et al (2012). The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.Cancer Discov2401–404. 10.1158/2159-8290.CD-12-0095
2
ChengC.WuX.ShenY.LiQ. (2020). KIF14 and KIF23 Promote Cell Proliferation and Chemoresistance in HCC Cells, and Predict Worse Prognosis of Patients with HCC.Cancer Manag Res1213241–13257. 10.2147/CMAR.S285367
3
CifolaI.PietrelliA.ConsolandiC.SevergniniM.ManganoE.RussoV.BellisG.D.BattagliaC.et al (2013). Comprehensive genomic characterization of cutaneous malignant melanoma cell lines derived from metastatic lesions by whole-exome sequencing and SNP array profiling.PLoS One8:e63597. 10.1371/journal.pone.0063597
4
DeRyckeM. S.GunawardenaS.MiddhaS.AsmannY.SchaidD.McDonnellS.RiskaS.EckloffB.et al (2013). Identification of novel variants in colorectal cancer families by high-throughput exome sequencing.Cancer Epidemiol Biomarkers Prev221239–1251. 10.1158/1055-9965.EPI-12-1226
5
FischerM.GrundkeISohrSQuaasMHoffmannSKnörckA.et al (2013). p53 and cell cycle dependent transcription of kinesin family member 23 (KIF23) is controlled via a CHR promoter element bound by DREAM and MMB complexes.PLoS One8:e63187. 10.1371/journal.pone.0063187
6
GaoC. T.RenJ.YuJ.LiS.GuoX.ZhouY. (2020). KIF23 enhances cell proliferation in pancreatic ductal adenocarcinoma and is a potent therapeutic target.Ann Transl Med81394. 10.21037/atm-20-1970
7
HuH.MuQ.BaoZ.ChenY.JiangT. (2018). Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor.Cell1751665–1678 e18. 10.1016/j.cell.2018.09.038
8
HuY.ZhengM.WangC.WangS.GouR.LiuO.et al (2020). Identification of KIF23 as a prognostic signature for ovarian cancer based on large-scale sampling and clinical validation.Am J Transl Res124955–4976. 10.21203/rs.2.23036/v1
9
IltzscheF.SimonK.StoppS.PattschullG.FranckeS.WolterP.et al (2017). An important role for Myb-MuvB and its target gene KIF23 in a mouse model of lung adenocarcinoma.Oncogene36110–121. 10.1038/onc.2016.181
10
KatoT.LeeD.WuL.PatelP.YoungA.WadaH.et al (2016a). Kinesin family members KIF11 and KIF23 as potential therapeutic targets in malignant pleural mesothelioma.Int J Oncol49448–456. 10.3892/ijo.2016.3566
11
KatoT.WadaH.PatelP.HuH. P.LeeD.UjiieH.et al (2016b). Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients.Lung Cancer9253–61. 10.1016/j.lungcan.2015.11.018
12
LiuX.ZhouT.KuriyamaR.EriksonR. L. (2004). Molecular interactions of Polo-like-kinase 1 with the mitotic kinesin-like protein CHO1/MKLP-1.J Cell Sci117(Pt 15), 3233–3246. 10.1242/jcs.01173
13
LiuX.EriksonR. L. (2007). The nuclear localization signal of mitotic kinesin-like protein Mklp-1: effect on Mklp-1 function during cytokinesis.Biochem Biophys Res Commun353960–964. 10.1016/j.bbrc.2006.12.142
14
LiT.LiY.GanY.TianR.WuQShuG.et al (2019). Methylation-mediated repression of MiR-424/503 cluster promotes proliferation and migration of ovarian cancer cells through targeting the hub gene KIF23.Cell Cycle181601–1618. 10.1080/15384101.2019.1624112
15
LiX. L.JiY.-M.SongR.LiX.-N.GuoL.-S. N. (2019). KIF23 Promotes Gastric Cancer by Stimulating Cell Proliferation.Dis Markers20199751923. 10.1155/2019/9751923
16
LiH.HandsakerB.WysokerA.FennellT.RuanJ.HomerN.et al (2009). The Sequence Alignment/Map format and SAMtools.Bioinformatics252078–2079. 10.1093/bioinformatics/btp352
17
LiH.DurbinR. (2009). Fast and accurate short read alignment with Burrows-Wheeler transform.Bioinformatics251754–1760. 10.1093/bioinformatics/btp324
18
LiangW. T.LiuX. F.HuangH. B.GaoZ. M.LiK. (2020). Prognostic significance of KIF23 expression in gastric cancer.World J Gastrointest Oncol.121104–1118. 10.4251/wjgo.v12.i10.1104
19
LiljeholmM.IrvineA. F.VikbergA. L.NorbergA.MonthS.SandströmH.et al (2013). Congenital dyserythropoietic anemia type III (CDA III) is caused by a mutation in kinesin family member, KIF23.Blood1214791–4799. 10.1182/blood-2012-10-461392
20
NislowC.LombilloV. A.KuriyamaR.McIntoshJ. R. (1992). A plus-end-directed motor enzyme that moves antiparallel microtubules in vitro localizes to the interzone of mitotic spindles.Nature359543–547. 10.1038/359543a0
21
SunL.ZhangC.YangZ.WuY.WangH.BaoZ.et al (2016). KIF23 is an independent prognostic biomarker in glioma, transcriptionally regulated by TCF-4.Oncotarget724646–24655. 10.18632/oncotarget.8261
22
SunX.JinZ.SongX.WangJ.LiY.QianX.et al (2015). Evaluation of KIF23 variant 1 expression and relevance as a novel prognostic factor in patients with hepatocellular carcinoma.BMC Cancer15:961. 10.1186/s12885-015-1987-1
23
TalevichE.ShainA. H.BottonT.BastianB. C. (2016). CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing.PLoS Computational Biology1210.1371/journal.pcbi.1004873
24
TakahashiS.FusakiN.OhtaS.IwahoriY.IizukaY.InagawaK.et al (2011). Downregulation of KIF23 suppresses glioma proliferation.J Neurooncol106519–529. 10.1007/s11060-011-0706-2
25
VikbergA. L.VooderT.LokkK.AnniloT.GolovlevaI. (2017). Mutation analysis and copy number alterations of KIF23 in non-small-cell lung cancer exhibiting KIF23 over-expression.Onco Targets Ther104969–4979. 10.2147/OTT.S138420
26
WangJ.CazzatoE.LadewigE.FrattiniV.RosenbloomD. I.ZairisS.et al (2016). Clonal evolution of glioblastoma under therapy.Nat Genet48768–776. 10.1038/ng.3590
27
YeL.LiH.ZhangF.LvT.LiuH.SongY. (2017). [Expression of KIF23 and Its Prognostic Role in Non-small Cell Lung Cancer: Analysis Based on the Data-mining of Oncomine].Zhongguo Fei Ai Za Zhi20822–826.
28
ZhuC.Bossy-WetzelE.JiangW. (2005). Recruitment of MKLP1 to the spindle midzone/midbody by INCENP is essential for midbody formation and completion of cytokinesis in human cells.Biochem J389(Pt 2), 373–381. 10.1042/BJ20050097
29
ZhaoC.WangX-BZhangY-HZhouY-MYinQYaoW-C(2018). MicroRNA-424 inhibits cell migration, invasion and epithelial-mesenchymal transition in human glioma by targeting KIF23 and functions as a novel prognostic predictor.Eur Rev Med Pharmacol Sci226369–6378.
30
ZhaoZ.ZhangK.WangQ.LiG.ZengF.ZhangY.et al (2021). Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Gliomas.Genomics Proteomics Bioinformatics10.1016/j.gpb.2020.10.005
31
ZouJ. X.DuanZ.WangJ.SokolovA.XuJ.ChenC.et al (2014). Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance.Mol Cancer Res12539–549. 10.1158/1541-7786.MCR-13-0459
Summary
Keywords
glioma, KIF23, malignancy, mutation, copy number alterations
Citation
Zhao Z, Wang Z, Bao Z-S, Gao W-Z, Zhang Y-D, Ruan C-J, Lv T, Wang Y and Sun L-H (2021) Mutation and Copy Number Alterations Analysis of KIF23 in Glioma. Front. Genet. 12:646929. doi: 10.3389/fgene.2021.646929
Received
06 January 2021
Accepted
06 April 2021
Published
03 May 2021
Volume
12 - 2021
Edited by
Silvia R. Rogatto, University of Southern Denmark, Denmark
Reviewed by
Mehdi Pirooznia, National Heart, Lung, and Blood Institute (NHLBI), United States; Nicoletta Coccaro, University of Bari Aldo Moro, Italy
Updates
Copyright
© 2021 Zhao, Wang, Bao, Gao, Zhang, Ruan, Lv, Wang and Sun.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Li-Hua Sun, sunnyshine1984@126.com
†These authors have contributed equally to this work
This article was submitted to Cancer Genetics and Oncogenomics, a section of the journal Frontiers in Genetics
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.